Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Head & Neck 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Lymphoma, Non-Hodgkin 4Lymphoma, B-Cell 3Carcinoma, Non-Small-Cell Lung 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Ovarian Neoplasms 2Multiple Myeloma 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Breast Neoplasms 2Urinary Bladder Neoplasms 1Stomach Neoplasms 1Recurrence 1Pancreatic Neoplasms 1Pancreatic Adenocarcinoma 1Nasopharyngeal Neoplasms 1Mesothelioma 1Liver Neoplasms 1Kidney Neoplasms 1Fallopian Tube Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Hepatocellular 1Burkitt Lymphoma 1Advanced Liver Cancers 1

Interventions

pembrolizumab 20Paclitaxel 13Fluorouracil 13Docetaxel 13Radiotherapy 12Oxaliplatin 11Cisplatin 11Capecitabine 8Carboplatin 7Leucovorin 6Cetuximab 5Nivolumab 4Albumin-Bound Paclitaxel 4atezolizumab 3Trastuzumab 3Ramucirumab 3Irinotecan 3Interleukin-2 3Injections 3Epirubicin 3Drug Therapy 3Dexamethasone 3130-nm albumin-bound paclitaxel 3tremelimumab 2tisotumab vedotin 2regorafenib 2patritumab deruxtecan 2oblimersen 2nedaplatin 2lenvatinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Esophageal Neoplasms × tocilizumab × Clear all
NCT05070247 2026-01-22

A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors

Takeda

Phase 1/2 Terminated
61 enrolled 29 charts
BreastGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Kidney Neoplasms, Liver Neoplasms, Mesothelioma, Nasopharyngeal Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡